found that dual inhibition of the epigenetic regulators DOT1L and EZH2 reversed the MYC-driven germinal center B cell malignant phenotype, providing a new differentiation therapeutic pathway for DLBCL (GCB subtype) (162). The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.